Kitphati Rungrueng, Pooruk Phisanu, Lerdsamran Hatairat, Poosuwan Siriwan, Louisirirotchanakul Suda, Auewarakul Prasert, Chokphaibulkit Kulkanya, Noisumdaeng Pirom, Sawanpanyalert Pathom, Puthavathana Pilaipan
National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.
Clin Vaccine Immunol. 2009 Jul;16(7):978-81. doi: 10.1128/CVI.00062-09. Epub 2009 May 20.
Anti-H5N1 antibody was determined by microneutralization, hemagglutination inhibition, and Western blotting assays in serial blood samples collected from eight Thai patients, including four fatal cases and four survivors. The antibody was detected as early as 5 days and, typically, with an increase in titer in paired blood at about 15 days after disease onset. The anti-H5 antibody response was long-lasting, for almost 5 years in cases which can be followed that far. In addition, cross-neutralizing activity to related clade 1 viruses was observed.
通过微量中和试验、血凝抑制试验和蛋白质印迹分析,对从8名泰国患者(包括4例死亡病例和4例幸存者)采集的系列血样中的抗H5N1抗体进行了检测。抗体最早在发病后5天即可检测到,通常在发病后约15天配对血样中的抗体滴度会升高。抗H5抗体反应具有持久性,在可随访到的病例中,这种反应可持续近5年。此外,还观察到对相关1类分支病毒的交叉中和活性。